News|Articles|November 1, 2024
AAV Production in Culture Biosciences’ 250mL Bioreactors
Author(s)Culture Biosciences
Adeno-associated virus (AAV) is a critical vector in gene therapy, but process robustness and scalability can pose challenges. This whitepaper demonstrates how Culture Biosciences' on-demand fleets of 250mL bioreactors enable large-scale experimentation and real-time data access to optimize upstream processes. Learn how process optimization can increase the fraction of full AAV capsids, accelerating your path to market.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
New Cellevate Nanofiber Microcarriers Aim to Transform Vaccine Manufacturing Processes
2
Analytics, Automation, and Quality Driving the Next Era of Drug Development
3
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
4
In KPMG's CEO Outlook, AI, Regulatory Demands, and Supply Chain Risk Rank High
5
